RankAlpha logo
Back to Rankings

PVLA

Palvella TherapeuticsC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-23
View Chart
Current thesis
PVLA now has positive Phase 3 SELVA data, an intended 2H 2026 NDA, and materially improved liquidity after the February 2026 financing, which together support a credible path to a first commercial product in a disease with no FDA-approved therapies [#PR-2026-02-24][#PR-2026-03-31].
Posture
Mixed
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta -7.5.
What can break
Commercial launch execution risk if approved in a rare-disease market.
Momentum
89
Value
41
Sentiment
34
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $125.00 · Bull $185.00 · Bear $70.00
Data freshness
Prices
As of 2026-07-23
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-17 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-23
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $229.00
Why
Momentum89 · Δ7d -7.5
Value41 · Δ7d -0.0
Sentiment34 · Δ7d +5.1
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
89
26% active weight
Current posture
7d trendSoftening
Δ7d
-7.5
Δ21d
+6.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
34
34% active weight
Current posture
7d trendImproving
Δ7d
+5.1
Δ21d
-5.1
Why this grade

Composite grade C. Momentum 88.7 / Value 41.1 / Sentiment 34.1

Fundamentals (TTM)
As of 2026-07-22
Market Cap
$2.04B
Beta
-0.15
Shares Out
14.34M
P/E (TTM) · Derived
-38.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-63.55
Rev YoY
-100.0%
EPS YoY
+62.1%
Gross Margin
+94.5%
Op Margin
-26594.3%
Net Debt
-$39.59M
Current Ratio
28.88
As of 2026-07-23 • Updated nightlySource: Internal modelMethodology